Sandbox Reserved 1096
From Proteopedia
| Line 1: | Line 1: | ||
{{Sandbox_ESBS_2019}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE --> | {{Sandbox_ESBS_2019}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE --> | ||
| - | ='''Human | + | ='''Human Peptidylarginine Deiminase Type 2''' = |
==General Description== | ==General Description== | ||
<Structure load='4N20' size='450' frame='true' align='right' caption='Insert caption here' scene='Insert optional scene name here' /> | <Structure load='4N20' size='450' frame='true' align='right' caption='Insert caption here' scene='Insert optional scene name here' /> | ||
| - | '''''Protein Arginine Deiminase type 2 ''''' also known as '''''PAD2''''', is a calcium-dependent [https://en.wikipedia.org/wiki/Enzyme enzyme] that catalyzes in humans the conversion of [https://en.wikipedia.org/wiki/Arginine Arginine] residues into [https://en.wikipedia.org/wiki/Citrulline Citrulline] in a [https://en.wikipedia.org/wiki/Post-translational_modification post-translational modification] referred to as [https://en.wikipedia.org/wiki/Citrullination Citrullination]. The structure of '''''PAD2 Apoenzyme''''' described here was elucidated at a calcium concentration of 0mM (Ca2+) with a resolution of 1.657 Å by [https://en.wikipedia.org/wiki/X-ray_crystallography x-ray diffraction cristallography]<ref name="PDB">[https://www.rcsb.org/structure/4N20</ref> . The biological assembly of PAD2 consists of a head-to-tail dimer with immunoglobin-like domains and a nucleophilic [https://en.wikipedia.org/wiki/Cysteine cysteine] residue responsible of catalytic activity in the active site <ref name="ART1">DOI:10.1021/cb500933j</ref>. | + | '''''Protein Arginine Deiminase type 2 ''''' also known as '''''PAD2''''', is a calcium-dependent [https://en.wikipedia.org/wiki/Enzyme enzyme] that catalyzes in humans the conversion of [https://en.wikipedia.org/wiki/Arginine Arginine] residues into [https://en.wikipedia.org/wiki/Citrulline Citrulline] in a [https://en.wikipedia.org/wiki/Post-translational_modification post-translational modification] referred to as [https://en.wikipedia.org/wiki/Citrullination Citrullination]. The structure of '''''PAD2 Apoenzyme''''' described here was elucidated at a calcium concentration of 0mM (Ca2+) with a resolution of 1.657 Å by [https://en.wikipedia.org/wiki/X-ray_crystallography x-ray diffraction cristallography]<ref name="PDB">[https://www.rcsb.org/structure/4N20</ref> . The biological assembly of PAD2 consists of a head-to-tail dimer with immunoglobin-like domains and a nucleophilic [https://en.wikipedia.org/wiki/Cysteine cysteine] residue responsible of catalytic activity in the active site <ref name="ART1">DOI:10.1021/cb500933j</ref>. In humans, five genes clustered in a single locus code for Arginine deiminases: ''PADI1,PADI2,PADI3,PADI4,PADI6''<ref name="ARTFr">DOI:10.1051/medsci/201127149</ref>. Expression of different isoforms of PAD seem to depend strongly on cell types and tissues even though PAD2 may be an ubiquist protein <ref name="ARTFr" />. Peptidyl Arginine Deiminase type 2 appears to have an essential role in the development of Breast Cancer, Multiple Sclerosis and other degenerative disorders thus making it a potential target for inhibitor design. |
==Structural Features== | ==Structural Features== | ||
==='''Primary, secondary and tertiary structure'''=== | ==='''Primary, secondary and tertiary structure'''=== | ||
Revision as of 23:12, 9 January 2020
| This Sandbox is Reserved from 25/11/2019, through 30/9/2020 for use in the course "Structural Biology" taught by Bruno Kieffer at the University of Strasbourg, ESBS. This reservation includes Sandbox Reserved 1091 through Sandbox Reserved 1115. |
To get started:
More help: Help:Editing |
Contents |
Human Peptidylarginine Deiminase Type 2
General Description
|
Protein Arginine Deiminase type 2 also known as PAD2, is a calcium-dependent enzyme that catalyzes in humans the conversion of Arginine residues into Citrulline in a post-translational modification referred to as Citrullination. The structure of PAD2 Apoenzyme described here was elucidated at a calcium concentration of 0mM (Ca2+) with a resolution of 1.657 Å by x-ray diffraction cristallography[1] . The biological assembly of PAD2 consists of a head-to-tail dimer with immunoglobin-like domains and a nucleophilic cysteine residue responsible of catalytic activity in the active site [2]. In humans, five genes clustered in a single locus code for Arginine deiminases: PADI1,PADI2,PADI3,PADI4,PADI6[3]. Expression of different isoforms of PAD seem to depend strongly on cell types and tissues even though PAD2 may be an ubiquist protein [3]. Peptidyl Arginine Deiminase type 2 appears to have an essential role in the development of Breast Cancer, Multiple Sclerosis and other degenerative disorders thus making it a potential target for inhibitor design.
Structural Features
Primary, secondary and tertiary structure
Calcium binding sites and active site
Catalysis of deimination
Citrullination of Arginine residues
Role in Human Health
Citrullination of Myelin Basic Protein (MBP) and Multiple Sclerosis
PAD2 and ER Target-gene Expression in Breast Cancer
Publication Abstract from ACS Publications [2]
Protein arginine deiminases (PADs) are calcium-dependent histone-modifying enzymes whose activity is dysregulated in inflammatory diseases and cancer. PAD2 functions as an Estrogen Receptor (ER) coactivator in breast cancer cells via the citrullination of histone tail arginine residues at ER binding sites. Although an attractive therapeutic target, the mechanisms that regulate PAD2 activity are largely unknown, especially the detailed role of how calcium facilitates enzyme activation. To gain insights into these regulatory processes, we determined the first structures of PAD2 (27 in total), and through calcium-titrations by X-ray crystallography, determined the order of binding and affinity for the six calcium ions that bind and activate this enzyme. These structures also identified several PAD2 regulatory elements, including a calcium switch that controls proper positioning of the catalytic cysteine residue, and a novel active site shielding mechanism. Additional biochemical and mass-spectrometry-based hydrogen/deuterium exchange studies support these structural findings. The identification of multiple intermediate calcium-bound structures along the PAD2 activation pathway provides critical insights that will aid the development of allosteric inhibitors targeting the PADs.
References
- ↑ [https://www.rcsb.org/structure/4N20
- ↑ 2.0 2.1 Slade DJ, Fang P, Dreyton CJ, Zhang Y, Fuhrmann J, Rempel D, Bax BD, Coonrod SA, Lewis HD, Guo M, Gross ML, Thompson PR. Protein Arginine Deiminase 2 Binds Calcium in an Ordered Fashion: Implications for Inhibitor Design. ACS Chem Biol. 2015 Jan 26. PMID:25621824 doi:http://dx.doi.org/10.1021/cb500933j
- ↑ 3.0 3.1 Mechin MC, Nachat R, Coudane F, Adoue V, Arnaud J, Serre G, Simon M. [Deimination or citrullination, a post-translational modification with many physiological and pathophysiological facets]. Med Sci (Paris). 2011 Jan;27(1):49-54. doi: 10.1051/medsci/201127149. PMID:21299962 doi:http://dx.doi.org/10.1051/medsci/201127149
